Skip to content

Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis

Rapid Diagnostics and Probiotic Therapy for Paediatric Acute Gastroenteritis - a Randomized, Factorial, Controlled, Placebo-controlled, Pilot Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02025452
Enrollment
76
Registered
2014-01-01
Start date
2014-03-31
Completion date
2014-12-31
Last updated
2017-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Gastroenteritis

Keywords

diarrhoea, gastroenteritis, rapid diagnostics, probiotics, sub-Saharan Africa

Brief summary

Many children admitted to hospital in Botswana without bloody diarrhoea are presumed to have viral gastroenteritis and so not treated with antibiotics - but they may indeed have a treatable cause for their illness. We will conduct a randomized trial to see if rapid testing using novel methods to identify potentially treatable causes of diarrhoea leads to improved outcomes. We will also be randomizing children to probiotic therapy versus placebo (the standard of care) to see if this treatment decreases the duration of diarrhoea. The proposed study is a pilot trial, necessary before embarking on a large multi-centre trial.

Interventions

OTHERRapid diagnostic

Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.

DIETARY_SUPPLEMENTProbiotic

Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months

OTHERPlacebo

Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.

Sponsors

Grand Challenges Canada
CollaboratorOTHER
BioGaia AB
CollaboratorINDUSTRY
Jeffrey Pernica
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Months to 60 Months
Healthy volunteers
No

Inclusion criteria

* acute non-bloody gastroenteritis

Exclusion criteria

* diarrhoea \> 14 days * sepsis, pneumonia, UTI, meningitis requiring empiric antibiotic therapy * malignancy, IBD * known link to another patient with diarrhoea of defined aetiology * transferred in already on antimicrobials * live outside study area * children with severe acute malnutrition will be eligible for diagnostic arm but not probiotic arm

Design outcomes

Primary

MeasureTime frame
Height z-score (HAZ) adjusted for initial HAZ60 days post-enrollment

Secondary

MeasureTime frameDescription
mortality60 days post-enrollment
environmental enteropathy score60 days post-enrollment
duration of diarrhoeaestimated average duration ~ 4 days.Note that presence of diarrhoea will be checked daily during admission. Total duration of diarrhoea will be verified with the caregiver by telephone 7 days after the participant was discharged home.
Weight z-score (WAZ) adjusted for initial WAZ60 days after enrolment

Countries

Botswana

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026